Table 5.
Flow Mediated Dilation (FMD), asymmetric dimethylarginine (ADMA), high sensitive C-reactive protein (hsCRP), interleukin-6 (IL-6), diacron reactive oxygen metabolite (dROM) and biological antioxidant potential (BAP) at baseline and after 8 weeks of placebo or piceatannol supplementation (a: men, b: women).
| a | Men | |||||||||||
| Non-Overweight | Overweight | |||||||||||
| Placebo (n = 5) | Piceatannol (n = 5) | Placebo (n = 5) | Piceatannol (n = 5) | |||||||||
| 0 Week | 8 Weeks | p | 0 Week | 8 Weeks | p | 0 Week | 8 Weeks | p | 0 Week | 8 Weeks | p | |
| FMD (%) | 7.0 ± 2.3 | 6.6 ± 2.1 | 0.8501 | 6.6 ± 4.8 | 8.4 ± 2.7 | 0.6037 | 7.5 ± 4.0 | 7.9 ± 3.9 | 0.7589 | 5.8 ± 3.9 | 5.1 ± 3.0 | 0.5940 |
| ADMA (nmol/mL) | 0.39 ± 0.04 | 0.40 ± 0.05 | 0.5734 | 0.37 ± 0.04 | 0.37 ± 0.03 | 0.7174 | 0.38 ± 0.04 | 0.40 ± 0.05 | 0.2205 | 0.37 ± 0.03 | 0.37 ± 0.05 | 0.7449 |
| hsCRP (ng/mL) | 597.8 ± 630.0 | 216.4 ± 141.9 | 0.4375 | 215.0 ± 105.8 | 627.8 ± 580.4 | 0.0625 | 2334.8 ± 3704.5 | 843.8 ± 459.5 | 0.6250 | 1086.4 ± 751.9 | 2255.4 ± 3869.1 | 1.0000 |
| IL-6 (pg/mL) | 1.22 ± 1.41 | 1.32 ± 1.90 | 0.8750 | 0.68 ± 0.31 | 0.90 ± 0.37 | 0.1250 | 1.76 ± 0.72 | 1.18 ± 0.38 | 0.1875 | 0.92 ± 0.08 | 0.80 ± 0.14 | 0.3125 |
| d-ROM (U. Carr) | 298.4 ± 94.5 | 266.2 ± 68.8 | 0.1546 | 275.6 ± 15.1 | 266.8 ± 60.9 | 0.7700 | 271.8 ± 66.3 | 268.4 ± 66.8 | 0.8592 | 317.8 ± 43.3 | 317.6 ± 89.0 | 0.9938 |
| BAP (pmol/L) | 2391.2 ± 317.3 | 2272.8 ± 195.8 | 0.3642 | 2250.8 ± 322.5 | 2276.6 ± 314.2 | 0.8604 | 2376.8 ± 214.5 | 2356.6 ± 238.6 | 0.8615 | 2136.2 ± 218.3 | 2385.8 ± 419.9 | 0.3506 |
| b | Women | |||||||||||
| Non-Overweight | Overweight | |||||||||||
| Placebo (n = 5) | Piceatannol (n = 5) | Placebo (n = 4) | Piceatannol (n = 5) | |||||||||
| 0 Week | 8 Weeks | p | 0 Week | 8 Weeks | p | 0 Week | 8 Weeks | p | 0 Week | 8 Week | p | |
| FMD (%) | 7.5 ± 1.6 | 7.8 ± 3.3 | 0.8795 | 8.0 ± 2.9 | 8.3 ± 3.6 | 0.7764 | 4.8 ± 2.1 | 5.8 ± 2.8 | 0.2860 | 6.8 ± 3.5 | 9.4 ± 2.1 | 0.0921 |
| ADMA (nmol/mL) | 0.36 ± 0.04 | 0.35 ± 0.03 | 0.3739 | 0.36 ± 0.05 | 0.36 ± 0.04 | 1.0000 | 0.45 ± 0.04 | 0.43 ± 0.03 | 0.6223 | 0.40 ± 0.06 | 0.40 ± 0.07 | 0.9264 |
| hsCRP (ng/mL) | 893.0 ± 1698.3 | 746.8 ± 671.0 | 0.6250 | 212.6 ± 233.1 | 117.6 ± 56.9 | 0.1250 | 1405.0 ± 1543.2 | 955.8 ± 953.8 | 0.3750 | 709.2 ± 703.7 | 889.8 ± 604.0 | 0.1875 |
| IL-6 (pg/mL) | 0.64 ± 0.24 | 1.30 ± 1.21 | 0.2500 | 0.92 ± 0.28 | 0.94 ± 0.21 | 1.0000 | 1.68 ± 0.59 | 1.37 ± 0.69 | 0.3750 | 1.50 ± 0.41 | 1.32 ± 0.38 | 0.6250 |
| d-ROM (U. Carr) | 349.8 ± 54.7 | 338.6 ± 20.7 | 0.6233 | 354.2 ± 37.8 | 308.6 ± 30.7 | 0.1607 | 349.3 ± 51.8 | 343.5 ± 10.8 | 0.8523 | 332.4 ± 31.8 | 362.4 ± 20.1 | 0.1058 |
| BAP (pmol/L) | 2359.2 ± 287.9 | 2407.6 ± 246.9 | 0.7853 | 2486.8 ± 182.9 | 2120.0 ± 207.7 | 0.0413 | 2151.0 ± 62.8 | 2135.8 ± 293.2 | 0.9202 | 2299.2 ± 178.5 | 2378.6 ± 430.6 | 0.6406 |